Replies to post #206525 on Biotech Values

[mr_o]

CELG/ BLUE

I would suspect by the time the program truly became "first line" and superseded Revlimd, Celgene would welcome the shift into a program with a longer patent expiration date.

P.S. Considering the BLUE program is for r/r multiple myeloma I don't think this will be an issue.

[masterlongevity]

daratumumab is already going to crush revlimid. by the time the blue drug makes (or if) it to market (5-6yrs), revlimid will be well on its way down. but it may still ahve some market for failure pts

[DewDiligence]

CELG acquires (private) Delinia for $300M up-front and $475M in contingent payments:

http://finance.yahoo.com/news/celgene-acquire-delinia-inc-120000484.html

The transaction expands Celgene’s Inflammation and Immunology pipeline through the acquisition of Delinia’s lead program, DEL106, as well as related second generation programs. DEL106 is a novel IL-2 mutein Fc fusion protein designed to preferentially upregulate regulatory T cells (Tregs), immune cells that are critical to maintaining natural self-tolerance and immune system homeostasis. Augmenting Tregs as a means of restoring immune system balance has the potential to benefit patients with a variety of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.